S

Shanghai Henlius Biotech Inc
HKEX:2696

Watchlist Manager
Shanghai Henlius Biotech Inc
HKEX:2696
Watchlist
Price: 22.5 HKD -3.02% Market Closed
Market Cap: 12.2B HKD

Shanghai Henlius Biotech Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai Henlius Biotech Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai Henlius Biotech Inc
HKEX:2696
Revenue
ÂĄ5.4B
CAGR 3-Years
109%
CAGR 5-Years
274%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
ÂĄ17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
ÂĄ7.5B
CAGR 3-Years
16%
CAGR 5-Years
84%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
ÂĄ5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
ÂĄ36.4B
CAGR 3-Years
12%
CAGR 5-Years
31%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
ÂĄ2.9B
CAGR 3-Years
59%
CAGR 5-Years
55%
CAGR 10-Years
N/A

Shanghai Henlius Biotech Inc
Glance View

Market Cap
12.2B HKD
Industry
Biotechnology

In the heart of China's bustling financial district, Shanghai Henlius Biotech Inc. stands proud as a beacon of innovation in the biopharmaceutical industry. Founded in 2010, Henlius has rapidly grown to become a notable player in the development of monoclonal antibodies, with a focus on oncology, autoimmune disorders, and ophthalmic conditions. The company's business model is rooted in its robust research and development capabilities, which are supported by strategic partnerships and a dedicated pipeline. By harnessing state-of-the-art technology and a global talent pool, Henlius crafts biosimilar and innovative biological drugs designed to meet the escalating health needs across the globe. With a strong focus on cutting-edge R&D, they have successfully commercialized several key products that have gained regulatory approval, allowing them to penetrate both domestic and international markets. Revenue flows into Henlius through a diversified portfolio that stretches beyond drug development to encompass manufacturing and sales partnerships. By leveraging their fully-integrated biopharmaceutical platform, Henlius not only develops its proprietary medications but also collaborates with other pharmaceutical giants to bring products to market efficiently. These collaborations often translate into licensing agreements and royalties, which provide Henlius with recurring income streams. The company's ability to navigate complex regulatory environments and its strategic expansion into global markets – including Europe, Southeast Asia, and Latin America – further reinforces its revenue-generating capacity. Thus, Henlius stands as a testament to the power of strategic ingenuity and cutting-edge science in the ever-evolving landscape of global healthcare.

Intrinsic Value
27.28 HKD
Undervaluation 18%
Intrinsic Value
Price
S

See Also

What is Shanghai Henlius Biotech Inc's Revenue?
Revenue
5.4B CNY

Based on the financial report for Dec 31, 2023, Shanghai Henlius Biotech Inc's Revenue amounts to 5.4B CNY.

What is Shanghai Henlius Biotech Inc's Revenue growth rate?
Revenue CAGR 5Y
274%

Over the last year, the Revenue growth was 68%. The average annual Revenue growth rates for Shanghai Henlius Biotech Inc have been 109% over the past three years , 274% over the past five years .

Back to Top